Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment

Bimonte, Sabrina; Leongito, Maddalena; Piccirillo, Mauro; Angelis, Cristina de; Pivonello, Claudia; Granata, Vincenza; Izzo, Francesco

doi:10.1186/s13027-016-0082-9

Cited by 7 publications

(7 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…been made in its etiology and treatment research, the prognosis of HCC remains poor (Bimonte et al, 2016;Gallicchio et al, 2016;Hamed et al, 2013;Nishida & Kudo, 2013;Sereni, Rodgers, Kirby, & Goykhman, 2017).…”

mentioning

confidence: 99%

Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma

Shali

Zhang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

High expression of ecto‐5′‐nucleotidase (CD73) has been reported in a number of epithelium origin malignancies. Here, we hypothesize that CD73 promotes hepatocellular carcinoma (HCC) growth and metastasis and that the effect is mediated by epithelial growth factor receptor (EGFR). HCC cells with different malignancies and Tissue microarrays of the tumor and peritumoral liver tissues from 30 independent patients were used to examine CD73 and EGFR expression. Then, MTT and Ki67 detection, together with cell adhesion, invasion, and migration assays were used to evaluate the effects of CD73 on cell growth and metastasis. The expression of EGFR in HCC cells was also tested after suppressing or overexpressing CD73. Lastly, tumor tissues from nude mice, which had been injected subcutaneously with HCC cells, were transplanted subcutaneously into CD73−/− and wild‐type (WT) C57 mice. CD73 expression was higher in HCC cells with greater metastatic potentials and tumor tissues compared with low metastatic cells and peritumor tissues. CD73 and EGFR were coexpressed and positively correlated in tumor and peritumor liver tissues in HCC tissue microarrays. Up‐regulationof CD73 by plasmid transfection or by pharmacological agents promoted EGFR expression in HCC cells, whereas suppression of CD73 inhibited these effects. The growth of transplanted tumor tissues was dramatically slower in CD73−/− mice than in WT type mice in the in vivo experiments. CD73 promotes HCC growth and metastasis and upregulated the expression of EGFR in HCC. Thus, CD73 and EGFR are potential targets in the treatment of HCC.

show abstract

mentioning

confidence: 99%

Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma

Shali

Zhang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…Our findings based on caliper and 18 F-FDG PET measurements of tumor volumes and Met max , as well as Metmean, are in concordance with the results reported by Willet and colleagues. Kim et al 3 measured CT-derived flow parameters and 18 F-FDG PET-derived SUV max , SUV mean , total lesion glycolysis, gray-level co-occurrence matrix (GLCM) entropy, and GLCM homogeneity in a case–control rabbit VX2 tumor model (used to model hepatocellular carcinoma) 29. Serial imaging performed up to 14 days following treatment with bevacizumab did not show any significant differences between the two groups of rabbits in any of the 18 F-FDG PET-derived metrics, whereas CT-derived blood flow and blood volume were different.…”

Section: Discussionmentioning

confidence: 99%

Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model

Bashir

Weeks²,

Goda³

et al. 2019

Nuclear Medicine Communications

View full text Add to dashboard Cite

Purpose Treatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab. Size measurements are inadequate to assess treatment response to these agents, and newer response assessment criteria are needed. We aimed to evaluate 18 F-FDG PET-derived texture parameters in a preclinical colorectal cancer model as alternative metrics of response to treatment with bevacizumab. Materials and methods Fourteen CD1 athymic mice injected in the flank with 5×106 LS174T cells (human colorectal carcinoma) were either untreated controls ( n =7) or bevacizumab treated ( n =7). After 2 weeks, mice underwent 18 F-FDG PET/CT. Calliper-measured tumor growth (Δ vol ) and final tumor volume (Vol cal ), 18 F-FDG PET metabolically active volume (Vol met ), mean metabolism (Met mean ), and maximum metabolism (Met max ) were measured. Twenty-four texture features were compared between treated and untreated mice. Immunohistochemical mean tumor vascular density was estimated by anti-CD-34 staining after tumor resection. Results Treated mice had significantly lower tumor vascular density ( P =0.032), confirming the antiangiogenic therapeutic effect of bevacizumab. None of the conventional measures were different between the two groups: Δ vol ( P =0.9), Vol cal ( P =0.7), Vol met ( P =0.28), Met max ( P =0.7), or Met mean ( P =0.32). One texture parameter, GLSZM-SZV (visually indicating that the 18 F-FDG PET images of treated mice comprise uniformly sized clusters of different activity) had significantly different means between the two groups of mice ( P =0.001). Conclusion 18 F-FDG PET derived texture parameters, particularly GLSZM-SZV, may be valid biomarkers of tumor response to treatment with bevacizumab, before change in volume.

show abstract

“…The VX2 tumor used in this study is a virus-induced anaplastic squamous cell carcinoma characterized by hypervascularity with rapid growth ( 18 19 ). The rabbit VX2 tumor model has been employed in numerous RFA-based studies for the treatment of HCC ( 20 21 22 23 ). After preparation of 4 mm 3 tumor chips from donor rabbits, midline subxiphoid laparotomy was performed in all 62 rabbits for liver tumor implantation into the subcapsular parenchyma in the left medial lobe of the liver.…”

Section: Methodsmentioning

confidence: 99%

No-Touch Radiofrequency Ablation of VX2 Hepatic Tumors In Vivo in Rabbits: A Proof of Concept Study

et al. 2018

View full text Add to dashboard Cite

ObjectiveIn a proof of concept study, we compared no-touch radiofrequency ablation (NtRFA) in bipolar mode with conventional direct tumor puncture (DTP) in terms of local tumor control (LTC), peritoneal seeding, and tumorigenic factors, in the rabbit VX2 subcapsular hepatic tumor model.Materials and MethodsSixty-two rabbits with VX2 subcapsular hepatic tumors were divided into three groups according to the procedure: DTP-RFA (n = 25); NtRFA (n = 25); and control (n = 12). Each of the three groups was subdivided into two sets for pathologic analysis (n = 24) or computed tomography (CT) follow-up for 6 weeks after RFA (n = 38). Ultrasonography-guided DTP-RFA and NtRFA were performed nine days after tumor implantation. LTC was defined by either achievement of complete tumor necrosis on histopathology or absence of local tumor progression on follow-up CT and autopsy. Development of peritoneal seeding was also compared among the groups. Serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6) were measured via ELISA (Elabscience Biotechnology Co.) after RFA for tumorigenic factor evaluation.ResultsRegarding LTC, there was a trend in NtRFA (80%, 20/25) toward better ablation than in DTP-RFA (56%, 14/25) (p = 0.069). Complete tumor necrosis was achieved in 54.5% of DTP-RFA (6/11) and 90.9% of NtRFA (10/11). Peritoneal seeding was significantly more common in DTP-RFA (71.4%, 10/14) than in NtRFA (21.4%, 3/14) (p = 0.021) or control (0%). Elevations of HGF, VEGF or IL-6 were not detected in any group.ConclusionNo-touch radiofrequency ablation led to lower rates of peritoneal seeding and showed a tendency toward better LTC than DTP-RFA.

show abstract

Radio-frequency ablation-based studies on VX2rabbit models for HCC treatment

Cited by 7 publications

References 72 publications

Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma

Ecto‐5′‐nucleotidase (CD73) is a potential target of hepatocellular carcinoma

Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model

No-Touch Radiofrequency Ablation of VX2 Hepatic Tumors In Vivo in Rabbits: A Proof of Concept Study

Contact Info

Product

Resources

About